Work

Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571

Year: 2002
Type: article
Study design: Case Report
Abstract: The Abl kinase inhibitor STI571 (imatinib mesylate) induces haematological remissions in many patients with chronic myeloid leukaemia (CML) but advanced stage CML usually becomes resistant to STI571. We describe a patient in whom progressive resistance to STI571 correlated with the appearance of a mutation in the Bcr-Abl kinase domain. This was a G to A transition that resulted in a glutamic acid to lysine substitution at position 255 (E255K) in the Abl type 1a protein. We suggest that the acquisition of point-mutations in the tyrosine kinase domain of Bcr-Abl may cause progressive clinical resistance to STI571.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W1985238075
FWCI: 3.243
Cites: 10
Cited by: 45
Related to: 9